中国白兔白介素-10基因的克隆、表达及其抗体的制备

目的克隆并表达中国白兔IL-10基因,制备抗IL-10多克隆抗体。方法运用RT-PCR对从ConA诱导后的中国白兔外周血单核细胞(PMBCr)总RNA中扩增IL-10基因,克隆后进行测序和遗传进化分析,同时将其亚克隆pET28a中,在大肠杆菌中诱导表达,并用纯化的表达产物制备多克隆抗体。结果该基因全长537 bp,编码178个氨基酸。与欧洲兔IL-10基因同源性很高,但与鼠、鸡、河豚和斑马鱼等不同物种IL-10基因差异较大。经IPTG诱导后,重组菌体裂解物经SDS-PAGE电泳可检测到相对分子质量为23.4×103的重组蛋白。Western blot分析表明,中国白兔IL-10基因已经表达。重组表达的蛋白量可占菌体蛋白的15.2%。结论成功实现了中国白兔IL-10的原核表达,制备了小鼠抗兔IL-10的多克隆抗体。     

斑马鱼心脏发育候选基因Pygo1多克隆抗体的制备及检测

Pygo1是心脏发育候选基因,可能在斑马鱼心脏发育过程中起着重要的调控作用.利用生物信息学选择斑马鱼Pygo1基因抗原亲水区,将扩增出的PCR片段克隆到原核表达pGEMT-4T-1载体中,转入E.coli中后通过IPTG(Isopropylβ-D-thiogalactoside)分别诱导表达GST融合蛋白.蛋白经纯化分离后用于免疫新西兰大白兔制备多克隆抗体.用Western Blot检测抗体的效价和特异性.     

斑马鱼Fbxl5基因多克隆抗体的制备与检测

Fbxl5为F-box基因家族的一员,目前研究发现其与心脏的发育有关。为了在斑马鱼模型中进一步研究该基因的功能,有必要制备其多克隆抗体。通过桥式PCR扩增出亲水性和特异性均好的斑马鱼Fbxl5基因片段,将其克隆入表达载体pET-28a,转化至大肠杆菌Rosseta中。用IPTG诱导Fbxl5重组质粒得到His-Fbxl5的融合蛋白。这个融合蛋白用Ni-IDA凝胶柱亲和纯化,将纯化的His-Fbxl5融合蛋白免疫新西兰大白兔制备多克隆抗体。使用Western Blot检测,获得了Fbxl5原核表达重组融合蛋白及高效价的特异性兔抗Fbxl5多克隆抗体。随后检测了Fbxl5在斑马鱼胚胎和成体组织中蛋白的表达,通过基因芯片分析在Fbxl5-MO和Std胚胎样品的mRNA含量差异.所得结果显示获得了较高效价和特异性好的斑马鱼Fbxl5多克隆抗体,为Fbxl5功能的进一步研究奠定了基础。     

小鼠OAZ2基因的原核表达及抗体制备

目的:克隆小鼠鸟氨酸脱羧酶抗酶2(OAZ2)功能基因,原核表达、纯化OAZ2蛋白并制备抗OAZ2多克隆抗体.方法:IRT-PCR法从鼠黑色素瘤细胞总RNA中克隆OAZ2 cDNA后,通过重叠延伸PCR技术构建无需移码即可全长翻译的功能基因.将OAZ2功能基因克隆人原核表达载体pET15b并原核表达.表达的蛋白经Ni-NTA亲和层析纯化后,用SDS-PAGE和Western Blot分析鉴定.用纯化的OAZ2蛋白作为抗原免疫Bab/C小鼠以制备多克隆抗体,制备抗体用ELISA和Western Blot检测抗体滴度和特异性.结果:成功获得小鼠OAZ2 cDNA并构建出无需移码翻译的OAZ2功能基因.OAZ2功能基因在大肠杆菌BL21(DE3)中可诱导性高表达并能用Ni-NTA树脂高效纯化.用纯化蛋白免疫Bab/C小鼠制备的抗血清经ELISA检测有较高的多克隆抗体效价(＞1∶64000),经Western blot鉴定可与纯化的OAZ2蛋白质特异性结合.结论:建立了鼠OAZ2蛋白原核表达和纯化技术,制备出高效价和特异性抗OAZ2多克隆抗体,为进一步研究OAZ2基因的功能奠定了基础.     

Nodal蛋白的表达、纯化及多克隆抗体制备

斑马鱼心脏发育模型中Nodal编码转录因子调节心脏的左右不对称发育,为了进一步研究Nodal信号途径在心脏发育中的调控作用和心脏疾病发生的分子机制,需要获得斑马鱼Nodal蛋白并制备其抗体.采用从斑马鱼心脏组织中提取RNA,通过反转录得到心脏组织各种表达基因的cDNA为模板,PCR扩增得到Nodal部分编码区序列,然后将其连接到pET-28a载体上获得原核表达.经酶切及测序鉴定后,转化Rosseta细菌,并用IPTG诱导表达融合蛋白,Ni-IDA凝胶柱亲和纯化,将纯化的融合蛋白免疫新西兰大白兔制备多克隆抗体,并用Western blotting检测抗体.获得了Nodal原核表达重组融合蛋白及高效价的特异性兔抗Nodal多克隆抗体,为Nodal功能的进一步研究奠定了基础.     

人类博卡病毒(HBoV)非结构蛋白NS1基因的克隆、原核表达及多克隆抗体的制备

目的:克隆、表达、纯化人类博卡病毒(HBoV)非结构蛋白NS1,制备抗NS1多克隆抗体。方法:利用PCR扩增HBoV非结构蛋白NS1基因,将其克隆至pMAL-c2X表达载体上,重组质粒转化大肠杆菌DH10B,IPTG诱导表达。表达的融合蛋白经Amylose Resin亲和层析柱纯化后,免疫新西兰大白兔制备多克隆抗体。用间接ELISA法检测抗体效价。结果:原核表达融合蛋白MBP-NS1,并获得了其多克隆抗体,抗体效价达到1∶32000。结论:在原核表达系统中表达、纯化了融合蛋白,制备抗NS1多克隆抗体,为进一步研究该病毒非结构蛋白基因的转录和翻译机制提供可靠的工具。     

利用DNA免疫技术制备WNT16蛋白多克隆抗体

Wnt16属于非经典wnt信号途径上的一员,目前有大量的研究表明wnt16与胚胎的血液发育和骨骼发育相关。为了阐明wnt16在造血过程中的调控机制,利用RT-PCR(逆转录PCR)扩增斑马鱼wnt16基因的ORF(开放阅读框)序列全长,构建真核表达载体pCAGGS-P7/wnt16,测序正确后,用该表达载体免疫BALB/c雌鼠,进行DNA免疫,制备斑马鱼抗WNT16特异性多克隆抗体。结果表明:通过DNA免疫制备的斑马鱼抗WNT16抗血清能特异性识别WNT16蛋白。斑马鱼WNT16抗体成功制备为进一步的功能研究奠定了重要基础。     

果蝇心脏发育标记基因Lbe抗体的制备与应用

黑腹果蝇(Drosophila melanogaster)的心脏发育调控基因与人类的相关基因具有高度同源性。Lbe基因是果蝇心脏发育的重要调控基因。为了深入研究Lbe基因在心脏发育中的调控功能,采用DNA免疫技术制备了抗果蝇Lbe蛋白的多克隆抗体。通过PCR扩增Lbe基因序列,将该序列与真核表达载体pCAGGS-P7同源重组,以该同源重组载体免疫4周龄小鼠,获得含有抗Lbe多克隆抗体的血清。蛋白质印迹(Western blot)和胚胎抗体染色结果表明,该抗体的特异性较好。该抗体为随后的Lbe功能的研究奠定了基础。     

卡尼鄂拉蜂锌转运蛋白-7相似蛋白（ZnT-7-like）的基因克隆、 抗体制备及差异表达

【目的】本研究旨在克隆卡尼鄂拉蜂Apis mellifera carnica锌转运蛋白 7相似蛋白（zinc transporter 7-like, ZnT-7-like）基因, 制备ZnT-7-like多克隆抗体, 了解该基因在卡尼鄂拉蜂王浆腺中不同时期的差异表达情况。【方法】运用RT PCR法从卡尼鄂拉蜂王浆腺总RNA中扩增ZnT-7-like基因, 进行生物信息学分析, 为避开跨膜结构的干扰, 选择克隆其部分序列（273 bp）作为多肽免疫序列。将其亚克隆入原核表达载体pGEX-4T-1, 转入大肠杆菌Escherichia coli BL21 （DE3）中诱导表达获得融合蛋白, 然后将融合蛋白纯化后免疫新西兰大白兔制备多克隆抗体, 分别用间接ELISA和Western blot检测抗体的效价和特异性, 最后采用实时荧光定量RT-PCR以及Western blot技术检测该基因在不同日龄成虫王浆腺中的相对表达量。【结果】克隆得到卡尼鄂拉蜂ZnT-7-like基因, 大小为1 065 bp。SDS-PAGE电泳结果显示融合蛋白成功表达; 制备的多克隆抗体效价高达1∶64 000, 且具有很高的特异性。ZnT-7-like在卡尼鄂拉蜂5个日龄成虫中的转录情况存在较大差异, 表现为3日龄成虫中的表达量极显著高于其他日龄（P<0.01）, 12日龄表达量最低, 其他日龄间表达量两两差异显著(P<0.05)或极显著（P<0.01）; ZnT-7-like蛋白表达与转录水平基本一致。【结论】成功克隆了卡尼鄂拉蜂ZnT-7-like基因, 制备了兔抗蜂ZnT-7-like多克隆抗体, 并在转录和翻译两个水平上测定了ZnT-7-like在卡尼鄂拉蜂王浆腺中不同时期的相对表达量。这些结果为深入研究卡尼鄂拉蜂ZnT-7-like基因的功能奠定了基础。     

Xenopus phospho-CDK7/cyclin H expressed in baculoviral-infected insect cells.

The cyclin-dependent kinase-activating kinase (CAK) catalyzes the phosphorylation of the cyclin-dependent protein kinases (CDKs) on a threonine residue (Thr160 in human CDK2). The reaction is an obligatory step in the activation of the CDKs. In higher eukaryotes, the CAK complex has been characterized in two forms. The first consists of three subunits, namely CDK7, cyclin H, and an assembly factor called MAT1, while the second consists of phospho-CDK7 and cyclin H. Phosphorylation of CDK7 is essential for cyclin association and kinase activity in the absence of the assembly factor MAT1. The Xenopus laevis CDK7 phosphorylation sites are located on the activation segment of the kinase at residues Ser170 and at Thr176 (the latter residue corresponding to Thr160 in human CDK2). We report the expression and purification of X. laevis CDK7/cyclin H binary complex in insect cells through coinfection with the recombinant viruses, AcCDK7 and Accyclin H. Quantities suitable for crystallization trials have been obtained. The purified CDK7/cyclin H binary complex phosphorylated CDK2 and CDK2/cyclin A but did not phosphorylate histone H1 or peptide substrates based on the activation segments of CDK7 and CDK2. Analysis by mass spectrometry showed that coexpression of CDK7 with cyclin H in baculoviral-infected insect cells results in phosphorylation of residues Ser170 and Thr176 in CDK7. It is assumed that phosphorylation is promoted by kinase(s) in the insect cells that results in the correct, physiologically significant posttranslational modification. We discuss the occurrence of in vivo phosphorylation of proteins expressed in baculoviral-infected insect cells.     

Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7

Addition of human papillomavirus (HPV) E7 CDK2/cyclin A or CDK2/cyclin E, purified from either insect cells or bacteria, dramatically upregulates histone H1 kinase activity. Activation is substrate specific, with a smaller effect noted for retinoblastoma protein (Rb). The CDK2 stimulatory activity is equivalent in high-risk (HPV type 16 [HPV16] and HPV31) and low-risk (HPV6b) E7. Mutational analyses of HPV16 E7 indicate that the major activity resides in amino acids 9 to 38, spanning CR1 and CR2, and does not require casein kinase II or Rb-binding domain functions. Synthetic peptides spanning HPV16 amino acid residues 9 to 38 also activate CDK2. Peptides containing this sequence that carry biotin on the carboxy terminus, as well as a photoactivated cross-linking group (benzophenone), also activate the complex and covalently associate with the CDK2/cyclin A complex in a specific manner requiring UV. Cross-linking studies that use protein monomers detect association of the E7 peptides with cyclin A but not CDK2. Together, our results indicate a novel mechanism whereby E7 promotes HPV replication by directly altering CDK2 activity and substrate specificity.     

Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop

Cyclin-dependent kinase 7 (CDK7) is the catalytic subunit of the metazoan CDK-activating kinase (CAK), which activates CDKs, such as CDC2 and CDK2, through phosphorylation of a conserved threonine residue in the T loop. Full activation of CDK7 requires association with a positive regulatory subunit, cyclin H, and phosphorylation of a conserved threonine residue at position 170 in its own T loop. We show that threonine-170 of CDK7 is phosphorylated in vitro by its targets, CDC2 and CDK2, which also phosphorylate serine-164 in the CDK7 T loop, a site that perfectly matches their consensus phosphorylation site. In contrast, neither CDK4 nor CDK7 itself can phosphorylate the CDK7 T loop in vitro. The ability of CDC2 or CDK2 and CDK7 to phosphorylate each other but not themselves implies that each kinase can discriminate among closely related sequences and can recognize a substrate site that diverges from its usual preferred site. To understand the basis for this paradoxical substrate specificity, we constructed a chimeric CDK with the T loop of CDK7 grafted onto the body of CDK2. Surprisingly, the hybrid enzyme, CDK2-7, was efficiently activated in cyclin A-dependent fashion by CDK7 but not at all by CDK2. CDK2-7, moreover, phosphorylated wild-type CDK7 but not CDK2. Our results suggest that the primary amino acid sequence of the T loop plays only a minor role, if any, in determining the specificity of cyclin-dependent CAKs for their CDK substrates and that protein-protein interactions involving sequences outside the T loop can influence substrate specificity both positively and negatively.     

A novel cyclin associates with M015/CDK7 to form the CDK-activating kinase

Phosphorylation by the CDK-activating kinase (CAK) is a required step in the activation of cyclin-dependent kinases. We have purified CAK from mammalian cells; the enzyme comprises two major polypeptides of 42 and 37 kDa. Protein sequencing indicates that the 42 kDa subunit is the mammalian homolog of M015, a protein kinase known to be a component of CAK in amphibians and echinoderms. Cloning of a cDNA encoding the 37 kDa subunit identifies it as a novel cyclin (cyclin H). We have reconstituted CAK in vitro with the MO15 catalytic subunit and cyclin H, demonstrating that M015 is a cyclin-dependent kinase (CDK7). Like other CDKs, MO15/CDK7 contains a conserved threonine required for full activity; mutation of this residue severely reduces CAK activity. The CAK holoenzyme activates complexes of CDK2 and CDC2 with various cyclins and also phosphorylates CDK2, but not CDC2, in the absence of cyclin. Thus, CAK is a CDK-cyclin complex implicated in the control of multiple cell cycle transitions.     

The cyclin D1-dependent kinase associates with the pre-replication complex and modulates RB.MCM7 binding

The capacity of the cyclin D-dependent kinase to promote G(1) progression through modulation of RB.E2F is well documented. We now demonstrate that the cyclin D1/CDK4 kinase binds to components of the MCM complex. MCM7 and MCM3 were identified as cyclin D1-binding proteins. Catalytically active cyclin D1/CDK4 complexes were incorporated into chromatin-bound protein complexes with the same kinetics as MCM7 and MCM3, where they associated specifically with MCM7. Although the cyclin D1-dependent kinase did not phosphorylate MCM7, active cyclin D1/CDK4, but not cyclin E/CDK2, did catalyze the dissociation of an RB.MCM7 complex. Finally, expression of an active D1/CDK4 kinase but not cyclin E/CDK2 promoted the removal of RB from chromatin-bound protein complexes. Our data suggest that D1/CDK4 complexes play a direct role in altering an inhibitory RB.MCM7 complex possibly allowing for setting of the origin in preparation for DNA replication.     

Cyclin B2/cyclin-dependent kinase1 dissociation precedes CDK1 Thr-161 dephosphorylation upon M-phase promoting factor inactivation in Xenopus laevis cell-free extract

Cyclin-dependent kinase 1 (CDK1) is the enzymatic subunit of M-phase Promoting Factor (MPF). It is positively regulated by phosphorylation on Thr-161 and association with a cyclin B molecule. The role of Thr-161 dephosphorylation upon MPF inactivation remains unclear; nevertheless, degradation of cyclin B is thought to be a direct cause of MPF inactivation. However, MPF inactivation actually precedes cyclin B degradation in Xenopus cell-free extracts. Here we study in details the temporal relationship between histone H1 kinase (reflecting MPF activity) inactivation, Thr-161 dephosphorylation, CDK1-cyclin B2 dissociation and cyclin B2 proteolysis in such extracts. We show an asynchrony between inactivation of histone H1 kinase and degradation of cyclin B2. CDK1 dephosphorylation on Thr 161 is an even later event than cyclin B2 degradation, reinforcing the hypothesis that cyclin B dissociation from CDK1 is the key event inactivating MPF. Cyclins synthesized along with MPF inactivation could deliver shortly living active MPF molecules, potentially increasing the asynchrony between histone H1 kinase inactivation and cyclin B2 degradation. We confirm this by showing that in the absence of protein synthesis, such a tendency is lower, but nevertheless, still detectable. Finally, to characterise better CDK1/cyclin B dissociation, we show that CDK1 begins to dissociate from cyclin B2 before the very beginning of cyclin B2 degradation and that the diminution in CDK1-associated cyclin B2 is faster than the decline of its total pool. Thus, neither cyclin B2 degradation nor Thr-161 dephosphorylation participates directly in CDK1 inactivation as measured by histone H1 kinase decline upon the exit from mitotic M-phase in Xenopus embryo extract.     

Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase

Cyclin-dependent kinase (CDK) 4 is a master integrator that couples mitogenic/oncogenic signalling cascades with the inactivation of the central oncosuppressor Rb and the cell cycle. Its activation requires binding to a D-type cyclin and then T-loop phosphorylation at T172 by the only identified CDK-activating kinase in animal cells, cyclin H-CDK7. In contrast with the observed constitutive activity of cyclin H-CDK7, we have recently identified the T172-phosphorylation of cyclin D-bound CDK4 as a crucial cell cycle regulatory target. Intriguingly, the homologous T177-phosphorylation of CDK6 is weak in several systems and does not present this regulation. In this Perspective, we review the recent advances and debates on the multistep mechanism leading to activation of D-type cyclin–CDK4 complexes. This involves a re-evaluation of the implication of Cip/Kip CDK “inhibitors” and CDK7 in this process.